This is an update to SPEC’s performance evaluation software for vendors and users of computing systems running Dassault ...

I recently asked NVIDIA CEO Jensen Huang a question in Houston, in the US, while engaging with the global powerhouses of AI, ...

French software giant positions knowledge as currency in the generative economy, announces three AI assistants, and deepens its partnership with NVIDIA.

The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Anchor your business to a stubborn, real-world problem customers cannot ignore. Replace hustle with systems that standardize decisions, data flow and accountability. Ambition isn’t what holds ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

The Senate Agriculture Committee released Monday a draft of its part of a digital assets market structure bill that could guide the future of the crypto industry in the U.S. Their draft includes a ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...